Guide Therapeutics, Inc. has patented technologies to efficiently screen nanoparticles, in order to identify those that target new tissues efficiently, selectively, and safely. The screening technology is based upon “DNA barcodes”, which are rationally designed DNA sequences. A nanoparticle is made to carry both a barcode and a reporter molecule that ‘reports’ if the payload has been delivered functionally into the cytoplasm or nucleus of the cell. In other words, the cell only reports if the drug has been delivered into the cell and the drug works. After administration in vivo, tissues and cells are harvested and those that are ‘reporter positive’ are identified by sequencing the barcodes. The proportion of a specific LNP can be analyzed by tissue and the characteristics of LNP’s showing high selectivity to target tissue and low selectivity to non-target tissue can be described. This approach enables Guide Therapeutics to generate in vivo drug delivery data at a rate this is up to 15,000-fold higher than a traditional experiment.
DNA barcoding is a step change in our ability to identify new nanoparticles for safe and effective gene therapies. It massively increases the speed of discovery by allowing screening of hundreds of particles at one time while identifying potential for toxicity in non-target tissue.
The Dahlman Lab has also shown the importance of in vivo screening, by showing that in vitro nanoparticle screens (which are used throughout the field to predict in vivo delivery) do not actually predict in vivo delivery. This demonstrates the importance of the Guide in vivo screening method.
We make 500 nanoparticles.
We barcode them.
We inject them all at once.
We look in all tissues.
We quantify delivery in all tissues.
We advance nanoparticles that optimize delivery.
We safely deliver genetic drugs.